Pharnext SCA
OTC:PNEXF

Watchlist Manager
Pharnext SCA Logo
Pharnext SCA
OTC:PNEXF
Watchlist
Price: 999 999.9999 USD Market Closed
Market Cap: 6T USD

EV/EBITDA
Enterprise Value to EBITDA

-194 995.7
Current
-208 438.1
Median
6.4
Industry
Higher than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-194 995.7
=
Enterprise Value
6T USD
/
EBITDA
-26m EUR
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
FR
Pharnext SCA
OTC:PNEXF
Average EV/EBITDA: 39.5
Negative Multiple: -194 995.7
N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.4
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
18
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.7
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -579.4 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.5
11%
1.5
AU
CSL Ltd
ASX:CSL
12.5
8%
1.6
NL
argenx SE
XBRU:ARGX
59.5
807%
0.1
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
158
N/A N/A
US
S
Seagen Inc
F:SGT
Negative Multiple: -66.4 N/A N/A

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
-207 687.7
2-Years Forward
EV/EBITDA
-454 156.3
3-Years Forward
EV/EBITDA
N/A